Ontology highlight
ABSTRACT:
SUBMITTER: Drilon A
PROVIDER: S-EPMC5857389 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Drilon Alexander A Laetsch Theodore W TW Kummar Shivaani S DuBois Steven G SG Lassen Ulrik N UN Demetri George D GD Nathenson Michael M Doebele Robert C RC Farago Anna F AF Pappo Alberto S AS Turpin Brian B Dowlati Afshin A Brose Marcia S MS Mascarenhas Leo L Federman Noah N Berlin Jordan J El-Deiry Wafik S WS Baik Christina C Deeken John J Boni Valentina V Nagasubramanian Ramamoorthy R Taylor Matthew M Rudzinski Erin R ER Meric-Bernstam Funda F Sohal Davendra P S DPS Ma Patrick C PC Raez Luis E LE Hechtman Jaclyn F JF Benayed Ryma R Ladanyi Marc M Tuch Brian B BB Ebata Kevin K Cruickshank Scott S Ku Nora C NC Cox Michael C MC Hawkins Douglas S DS Hong David S DS Hyman David M DM
The New England journal of medicine 20180201 8
<h4>Background</h4>Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.<h4>Methods</h4>We enrolled patients with consecutively and prospectively identified TRK fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase ...[more]